LONDON, May 11, 2010 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) (Silence or the Company) announces that Philip Haworth, Ph.D., chief executive officer, will present corporate updates at two upcoming industry and financial conferences. Dr. Haworth's presentations will focus on Silence Therapeutics' comprehensive RNA interference (RNAi) therapeutics platform, broad clinical-stage pipeline and multiple ongoing collaborations with leading pharmaceutical companies.
Upcoming conferences at which the Company will present include: Rodman Renshaw 6th Annual Global Healthcare Conference May 16-18, 2010 Grosvenor House Hotel, London, UK Silence's presentation: 9:25 a.m. (BST) on Tuesday, May 18, 2010. A live webcast of the presentation will be available at www.silence-therapeutics.com and will be archived for 90 days. BioEquity Europe 2010 May 19-20, 2010 Swissotel Zurich, Zurich, Switzerland Silence's presentation: 1:30 p.m. (CEST) on Thursday, May 20, 2010.
About Silence Therapeutics plc (http://www.silence-therapeutics.com)
Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX(TM), a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. A second, complementary delivery technology known as PolyTran(TM) uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration. Additionally, the company has a platform of novel short interfering RNA (siRNA) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.
The company's strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts on three patent families associated with the Zamore Design Rules, which cover broad structural features of siRNA design for more potent next generation siRNA sequences.
Silence Therapeutics is headquartered in London, UK, with research and development operations in Berlin and Palo Alto, CA.
Forward-Looking Statements
This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.
SOURCE: Silence Therapeutics plc
CONTACT: Phil Haworth of Silence Therapeutics, +1-650-855-1514,p.haworth@silence-therapeutics.com; or Richard Potts, or Jonathan Senior,both of Nomura Code Securities, +44-020-7776-1200, for SilenceTherapeutics; or media, Tim Brons, +1-415-675-7400,tbrons@vidacommunication.com, or investors, Stephanie Diaz,+1-415-675-7400, sdiaz@vidacommunication.com, both of Vida Communicationfor Silence Therapeutics
Comments